These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37340561)

  • 1. GLP-1 agonists for people living with HIV and obesity, is there a potential?
    Zino L; Tack CJ; Richel O; Burger DM
    HIV Med; 2023 Oct; 24(10):1029-1034. PubMed ID: 37340561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
    Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
    Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
    Herrou J; Mabilleau G; Lecerf JM; Thomas T; Biver E; Paccou J
    Calcif Tissue Int; 2024 Feb; 114(2):86-97. PubMed ID: 37999750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
    O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
    Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.
    Jensterle M; Janež A
    Horm Res Paediatr; 2023; 96(6):599-608. PubMed ID: 34852347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.
    Hu EH; Tsai ML; Lin Y; Chou TS; Chen TH
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 agonists: A review for emergency clinicians.
    Long B; Pelletier J; Koyfman A; Bridwell RE
    Am J Emerg Med; 2024 Apr; 78():89-94. PubMed ID: 38241775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
    Amaro A; Sugimoto D; Wharton S
    Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review.
    Jensterle M; Rizzo M; Haluzík M; Janež A
    Adv Ther; 2022 Jun; 39(6):2452-2467. PubMed ID: 35503498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new era for glucagon-like peptide-1 receptor agonists].
    Neuville MF; Paquot N; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
    Taha MB; Yahya T; Satish P; Laird R; Agatston AS; Cainzos-Achirica M; Patel KV; Nasir K
    Curr Atheroscler Rep; 2022 Aug; 24(8):643-654. PubMed ID: 35624390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
    Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
    Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.
    Popoviciu MS; Păduraru L; Yahya G; Metwally K; Cavalu S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Christensen RM; Juhl CR; Torekov SS
    Drug Saf; 2019 Aug; 42(8):957-971. PubMed ID: 30972641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.